Last reviewed · How we verify
K-924 HD
K-924 HD is a selective aldosterone antagonist that blocks mineralocorticoid receptor signaling to reduce sodium retention and blood pressure.
K-924 HD is a selective aldosterone antagonist that blocks mineralocorticoid receptor signaling to reduce sodium retention and blood pressure. Used for Hypertension, Heart failure.
At a glance
| Generic name | K-924 HD |
|---|---|
| Sponsor | Kowa Company, Ltd. |
| Drug class | Mineralocorticoid receptor antagonist |
| Target | Mineralocorticoid receptor (MR) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
K-924 HD acts as a non-steroidal mineralocorticoid receptor antagonist, inhibiting aldosterone-mediated sodium reabsorption in the collecting duct of the kidney. This mechanism reduces fluid volume and blood pressure while potentially preserving potassium levels compared to traditional potassium-sparing diuretics. The drug is being developed for hypertension and heart failure indications.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Hyperkalemia
- Dizziness
- Headache
Key clinical trials
- K-924 Phase III Confirmatory Study (PHASE3)
- K-924 Phase III Long Term Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |